Perspective Therapeutics, Inc. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Filing contains presentation slides on Perspective's 212Pb-based radiopharmaceutical programs: VMT-α-NET (neuroendocrine tumors, Phase 1/2a with 68 patients showing durable responses), VMT01 (melanoma, Phase 1/2a with preliminary anti-tumor activity at 3.0 mCi dose), and PSV359 (FAP-targeted solid tumors, Phase 1/2a). No new financing, partnerships, or material corporate events disclosed; this is portfolio overview material presented at a conference (ASCO 2026 referenced).
Why this rating
Early-stage pipeline updates with no quantified efficacy endpoints, regulatory milestones, partnerships, or financing. Routine clinical data presentation; immaterial to $212.9M market cap.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.